scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Bought by Rubric Capital Management LP

Rubric Capital Management LP lifted its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 35.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,775,000 shares of the company’s stock after buying an additional 1,250,000 shares during the quarter. Rubric Capital Management LP owned approximately 9.54% of scPharmaceuticals worth $21,774,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in SCPH. BNP Paribas Financial Markets increased its stake in shares of scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after purchasing an additional 3,101 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of scPharmaceuticals in the third quarter worth $57,000. King Luther Capital Management Corp raised its holdings in shares of scPharmaceuticals by 0.9% in the third quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock worth $10,150,000 after acquiring an additional 20,650 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after acquiring an additional 14,866 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its position in scPharmaceuticals by 25.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 621,665 shares of the company’s stock worth $2,835,000 after purchasing an additional 124,438 shares in the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Stock Up 5.6 %

scPharmaceuticals stock opened at $3.60 on Wednesday. The stock has a fifty day moving average price of $4.24 and a 200 day moving average price of $4.43. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a 52 week low of $3.08 and a 52 week high of $6.71.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Craig Hallum lowered their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Thursday, November 14th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.